GE Healthcare looks to self-manufacture imaging agent Optison

01/16/2013 | Pharmaceutical Business Review Online

GE Healthcare is seeking approval to independently manufacture Optison, a contrast agent for cardiac imaging. The company has submitted a supplemental new drug application for the agent to U.S. regulators. "While we cannot predict a timeline for regulatory authority approval, we look forward to servicing the U.S. cardiology community directly in 2013," said GE Healthcare's Stephen Lightfoot.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD